[ad_1]
The final results of the Moderna vaccine against Covid-19 confirm that it is 94% effective and that none of those vaccinated developed any serious diseases, the company said, starting the approval process by regulators around the world.
The American company is beginning to submit its data to regulatory authorities in the US, Europe and the UK for an emergency permit.
He also hopes that the US Food and Drug Administration will consider his application at its December 17 meeting, Moderna said.
Who will get the vaccine and when
The UK bought 7 million doses of the vaccine: 5 million on the day Moderna announced an intermediate effect of 94.5% and another 2 million last week. However, the UK supply of the vaccine is not expected until March. Modern, based in Massachusetts, has received 2.48 billion. dollars in U.S. federal funds and was a key part of the Trump administration.
Although it has agreements around the world, the United States will be the first to agree. Moderna said it expects to have 20 million doses of its vaccine ready for use in the United States by the end of this year. In August, they also bought 100 million shares with an optional option for an additional 400 million. Moderna says it is on track to build between 500 million and 1 billion doses for global distribution by 2021, according to The Guardian.
Like Pfizer / BioNTech, Moderna has used new mRNA technology to develop its vaccine that contains the genetic code of the virus and not any attenuated or deadly parts of it. The two companies announced remarkable and very similar results. Final data analysis from Pfizer gave the vaccine 95% efficacy.
Vaccine costs
Moderna becomes the third company to submit its data for approval, after Pfizer and after AstraZeneca. Moderna vaccine is said to be stored for a month at normal refrigerator temperature once it comes out of the freezer, but the cost will be prohibitive in many parts of the world. In August, the company said it would charge between $ 32 and $ 37 per payment. The Oxford vaccine will cost less than £ 3 per dose.
Mortality rate and side effects
Moderna’s phase 3 analysis included 30,000 people who received the vaccine in the United States, of whom 196 became ill. Thirty people became seriously ill and one died, but none had received the Moderna vaccine. The trials included a significant number of people in vulnerable groups, with 7,000 people over 65 and more than 5,000 younger people with chronic diseases such as diabetes, severe obesity, and heart disease.
The company said there are no serious side effects. The most common were hand pain, headaches, and fatigue. Full test data has not been released, but will be released in due course, Moderna said.
Read them News of Greece and the world, with its reliability and validity News247.gr.
[ad_2]
